Neoadjuvant therapy for locally invasive bladder cancer. 1989

E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
Department of Urology, Nara Medical University, Japan.

The present investigation was conducted to examine the effect of neoadjuvant PVB and CAP regimens for locally invasive bladder cancer and consisted of two studies: (1) a retrospective nonrandomized study of neoadjuvant PVB therapy, and (2) a well-controlled randomized study of neoadjuvant CAP therapy. A total of 25 patients with primary locally invasive bladder cancer were entered into the PVB study between January 1981 and December 1985. Since 1986, 31 patients have been randomized into the CAP study. In the PVB-treated group, a 71.4% complete response (CR) plus partial response (PR) rate and a 71.4% downstaging were noted. On the other hand, in the CAP-treated group, a 50.0% CR plus PR rate and a 88.9% downstaging were noted. The 2- and 5-year survival rates of neoadjuvant PVB were 78.6 and 60.6%, respectively. In contrast, the 2-year survival rate of the neoadjuvant CAP-treated group was 100% at a mean follow-up of 15.8 months. No statistical significance was achieved in the survival rates. These results indicated that neoadjuvant PVB and CAP would be useful in the management of invasive bladder cancer.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009361 Neoplasm Invasiveness Ability of neoplasms to infiltrate and actively destroy surrounding tissue. Invasiveness, Neoplasm,Neoplasm Invasion,Invasion, Neoplasm
D001749 Urinary Bladder Neoplasms Tumors or cancer of the URINARY BLADDER. Bladder Cancer,Bladder Neoplasms,Cancer of Bladder,Bladder Tumors,Cancer of the Bladder,Malignant Tumor of Urinary Bladder,Neoplasms, Bladder,Urinary Bladder Cancer,Bladder Cancers,Bladder Neoplasm,Bladder Tumor,Cancer, Bladder,Cancer, Urinary Bladder,Neoplasm, Bladder,Neoplasm, Urinary Bladder,Tumor, Bladder,Tumors, Bladder,Urinary Bladder Neoplasm
D001761 Bleomycin A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2. It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. BLEO-cell,Blanoxan,Blenoxane,Bleolem,Bleomicina,Bleomycin A(2),Bleomycin A2,Bleomycin B(2),Bleomycin B2,Bleomycin Sulfate,Bleomycins,Bleomycinum Mack,Bléomycine Bellon,BLEO cell,BLEOcell,Bellon, Bléomycine,Mack, Bleomycinum,Sulfate, Bleomycin
D002295 Carcinoma, Transitional Cell A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS. Carcinomas, Transitional Cell,Cell Carcinoma, Transitional,Cell Carcinomas, Transitional,Transitional Cell Carcinoma,Transitional Cell Carcinomas
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females

Related Publications

E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
April 1992, Hinyokika kiyo. Acta urologica Japonica,
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
July 1996, European journal of cancer (Oxford, England : 1990),
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
July 2020, Expert review of anticancer therapy,
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
January 2011, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
June 2021, Clinical oncology (Royal College of Radiologists (Great Britain)),
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
July 2005, Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
July 2019, European urology,
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
July 2017, World journal of surgery,
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
August 1997, Hinyokika kiyo. Acta urologica Japonica,
E Okajima, and S Ozono, and Y Hirao, and K Babaya, and H Aoyama, and Y Maruyama, and S Samma, and A Iwai, and H Momose
November 2001, Gan to kagaku ryoho. Cancer & chemotherapy,
Copied contents to your clipboard!